

**LIFE SCIENCE 2012**

学术研讨会

# Call for posters

**CALSS Annual Conference**

GEP ETH Zentrum, Zurich

Sunday, February 12, 2012

[http://www.calss.ch/open.php?news\\_ID=228](http://www.calss.ch/open.php?news_ID=228)

瑞士中国学人生命科学协会

Chinese Association of Life Science in Switzerland (CALSS)



# 瑞士中国学生生命科学协会

Chinese Association of Life Science in Switzerland (CALSS)

E-Mail: [calss2009@gmail.com](mailto:calss2009@gmail.com); Website: [www.CALSS.ch](http://www.CALSS.ch)

## 2012年学术研讨会

### Life Science Symposium 2012

#### 演讲嘉宾 /Speakers:

**Prof. Yihai Cao /曹义海 教授** (Karolinska Institute, Stockholm, Sweden)

**Dr. Christian H. Leist** (Leading Scientist of Novartis Pharma Ltd, Basel)

**Dr. Yinghua Tian /田英华 博士** (Zurich University Hospital, Zurich)

**Mr. Domenico P. Alexakis** (CEO, Swiss Biotech Association, Zurich)

**Dr. Haifeng Ye /叶海峰 博士** (D-BSSE, ETHZ, Basel)

会议注册 /Registraton: <http://alturl.com/nevyo>

研究海报摘要提交 /Poster abstract submission: <http://alturl.com/q3ibe>

#### 时间 /Time:

14:00-19:00, Sunday, February 12, 2012.

#### 地点 /Venue:

GEP, ETH Zentrum, Rämistrasse 101, Zurich

外地会员参会将获得交通补助 /Non-local members of CALSS will get standard travel allowance


特设海报大奖，欢迎提交摘要

一等奖1名 (200 CHF), 二等奖2名 (各100 CHF), 三等奖5名 (各50 CHF)

## Program / 会议议程

- 13:30 – 14:00 Poster session  
研究海报展示
- 14:00 – 14:15 Speech by Ms. Sun Ling, Counselor of Education, Embassy of PRC  
教育处孙玲参赞致辞
- 14:15 – 15:00 Prof. Yihai Cao / 曹义海 教授  
**Angiogenesis in cancer and fat: A common target for therapy**  
血管生成: 治疗肿瘤和肥胖的通用临床靶标
- 15:00 – 15:45 Dr. Christian H. Leist,  
**The importance of Implementing 'built-in quality concept' for global biomanufacturing expansion and success**  
执行“质量控制理念”对生物制造的全球扩张及成功的重要性
- 15:45– 16:15 Dr. Yinghua Tian / 田英华 博士  
**Activation of Serotonin Receptor-2B Rescues Small-for-Size Liver Graft Failure**  
5-羟色胺受体活化与小体积肝脏移植
- 16:15– 16:45 中间休息及海报展示  
Coffee break and poster session
- 16:45– 17:30 Mr. Domenico P. Alexakis  
**Swiss Biotech – Introduction of a future-oriented Industry**  
生物技术：瑞士工业的明天
- 17:30– 18:15 Dr. Haifeng Ye / 叶海峰 博士  
**New solution for diabetes: blue light-based therapy**  
糖尿病患者的福音: 光疗
- 18:15– 18:30 海报颁奖 /Poster awards
- 18:30– 19:30 自助晚餐 /Buffet dinner

## About the speakers:



### Prof. Yihai Cao

[yihai.cao@ki.se](mailto:yihai.cao@ki.se)

Prof. Cao was born in Shandong, China and received his medical training at the Medical School, Shandong University in 1983. 1983-1986, he received further basic and clinical training from the Chinese Academy of Medical Sciences and from the Ludwig Institute for Cancer Research, Switzerland. He obtained his Ph.D. degree in 1993 from the Karolinska Institutet, followed by a 3-yr postdoctoral training period at the Harvard Medical School, Children's Hospital (Dr. Judah Folkman's Laboratory), Boston, Massachusetts, USA. He returned to the Karolinska Institutet in 1996 and became a full professor in 2004. He received a honorary medical degree (M.D.) from Copenhagen University, Denmark, 2006. He is currently a guest professor at the Linköping University, Sweden. He received the Fernstrom research prize. In 2010, Dr Cao received the distinguished professor award at the Karolinska Institutet. Dr. Cao also received the ERC-advanced research grant award for being the top scientist in Europe. His research interests include molecular mechanisms of pathological angiogenesis that contributes to obesity, metabolic diseases, diabetic complications, cancer, metastasis, and cardiovascular diseases, with emphasis on clinical relevance and translational research. He has published more than 160 research articles, which have been cited more than 11 000 times.

### Selected publications:

1. Cell 79; 315-328, 1994.
2. Science 273, 510-513, 1996.
3. Nature, 398, 381, 1999.
4. Nature, 414, 550-554, 2001.
5. Cancer Cell, 1, 99-108, 2002.
6. Nature Medicine, 9, 604-613, 2003.
7. Cancer Cell, 6,333-345, 2004.
8. Nature Medicine,11(7):780-785, 2005.
9. Nature Reviews-Cancer,5:735-43, 2005.
10. Cell Metabolism. 7;9(1):99-109, 2009.
11. Science Signaling, 2(59):re1, 2009
12. Science Translational Medicine, 15ps3, 2010.
13. Nature Rev-Drug Discovery,9,107-115., 2010
14. Nature Protocol, 5, 912-920, 2010,
15. Nature Clinical Oncology,7:604-8, 2010
- 16: Nature Medicine, in press, 2011
17. Science Translational Medicine, in press, 2011
18. Nature Protocol. 5:1911-8. 2010
19. Nature Protocol. 5:1903-10, 2010
20. Nature Protocol. 6:817-26, 2011



## **Dr. Christian Leist**

[christian.leist@novartis.com](mailto:christian.leist@novartis.com)

Dr. Christian Leist is the head of the Bioprocess Development Group in the Department of Biotechnology Development at Novartis Pharma Ltd in Basel and is also responsible for the development and implementation of related new key technologies.

After attaining his masters degree in biology at the University of Zurich, Christian went on to complete his Ph.D. thesis at the Swiss Federal Institute of Technology of Zurich (ETH), graduating with distinction in Bioprocess Engineering. After working as an assistant professor in Cell Culture Technology at the ETH, Christian moved to Novartis in 1989, where he has held several positions as lab and group head in the fields of Biotechnology Development. His activities in development and implementation of PAT-technology in Bioprocess Development were distinguished in 2000 when he received the Novartis Leading Scientist Award. In 2008 Christian Leist and his team received the “Swiss Technology Award 2007” for the development of an automated online monitoring system for the cellular energy charge of animal cells in culture, the “ATP-Master”

Currently, Christian maintains a part-time teaching position at the ETH Zurich and is also a Swiss Delegate of the working group Bioreactor Performance of the European Federation of Biotechnology (EFB). He is well known in the biotechnology community and is regularly invited to speak and chair sessions at international biotechnology congresses, having also published many articles in well-known peer-reviewed journals. He has supervised more than 60 students performing traineeships, Masters dissertations and Ph.D. theses and is an active member of the Swiss Work Group on Gene Technology of the FDP political party in Bern.

In addition to these responsibilities, Christian has held a teaching position at the Technical University of Winterthur and has been actively involved as a Novartis delegate of ACTIP, the Industrial Reference Group in Sweden and in the ICH/EFPIA Quality Task Force group. Christian has also been invited to serve as a technical expert on the ESA review commission for the “Review of Proposals for Topical Teams in Biotechnology including Biomedical Engineering”, ESA-Headquarters, Paris (F) and for the Venture Capital Program „Venture 2000, 2002, 2004, 2006, 2008 and 2010” of McKinsey and ETH Zürich.



**PD Dr. med. Yinghua Tian:**

[yinghuatian@hotmail.com](mailto:yinghuatian@hotmail.com)

Prof. Tian has been a clinical transplant surgeon for 12 years, and worked on transplantation research over 16 years. Currently, Prof. Tian is a PD Dr. med, the director of Transplantation and Microsurgery laboratory, Department of Visceral & Transplantation Surgery, University Hospital of Zürich.

**Selected publications:**

Activation of serotonin receptor-2B rescues small-for-size liver graft failure in mice. *Hepatology*. 2011, 53(1):253-62.

Kidney transplantation in mice using left and right kidney grafts. *J Surg Res*. 2010, 163(2):e91-7. Epub 2010 May 8.

Kupffer cell-dependent TNF-alpha signaling mediates injury in the arterialized small-for-size liver transplantation in the mouse. *Proc Natl Acad Sci U S A*. 2006,103(12):4598-603. Epub 2006 Mar 13.

Arterialized partial orthotopic liver transplantation in the mouse: a new model and evaluation of the critical liver mass. *Liver Transpl*. 2003, 9(8):789-95.



Dr. Haifeng Ye

[haifeng.ye@bsse.ethz.ch](mailto:haifeng.ye@bsse.ethz.ch)

Haifeng Ye is currently a Ph.D candidate at Department of Biosystems Science and Engineering (D-BSSE), ETH Zurich.

Ye's research interest has been focused on mammalian cell engineering and biotechnology, with the goal to achieve generic and prototypic advances in human therapy by capitalizing on an interdisciplinary systems approach and exploiting progress in basic research. He has successfully designed a light-inducible transgene expression system (optogenetic transcription device), which holds great promise for pharmacological dosing of in-situ-produced protein therapeutics as well as therapeutic reprogramming of endogenous gene networks, as exemplified by a revolutionized approach for diabetic treatment.

Key publication:

[A synthetic optogenetic transcription device enhances blood glucose homeostasis in mice.](#) **Science**, 2011, 332:1565-1568.

Highlighted by:

1. *ScienceDaily*
  2. *Cell*, 2011, 146: 495
  3. *Nature medicine*, 2011, 17:939
  4. *Nature Chemical Biology*, 2011, 7: 497
  5. *Swiss TVs*
- et. al.*